Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Dec 27;4(1):vdab185. doi: 10.1093/noajnl/vdab185

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 1. — Illustrative examples of GammaTile® (GT) dosimetry and local control. (A) Patient 1 developed new contrast enhancement outside of the HR-CTV (See Methods). Preoperative axial, coronal, and sagittal MR postgadolinium T1 images (top row) and corresponding postoperative images (second row) are shown. GT dosimetry is shown on the third row. The green line indicates the HR-CTV. Axial, coronal, and sagittal MR postgadolinium T1 images at the time of recurrence are shown in the fourth row. (B) Patient 13 developed new contrast enhancement within the HR-CTV. The arrangement of images is described in (A). Hematoxylin and eosin (H&E) staining of the clinical specimen derived from resection of the contrast-enhancing lesion is shown in the rightmost panel on the fourth row. Pathology review of the sample revealed the presence of active tumor, indicating tumor recurrence.